Patents by Inventor Michael Mutz

Michael Mutz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10919887
    Abstract: The invention provides new solid forms, salts and polymorphs of 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid (referred to herein as Compound X), pharmaceutical compositions containing them, and processes for their manufacture and use in therapy.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: February 16, 2021
    Assignee: Novartis AG
    Inventors: Eric Aubin, Anthony Casarez, Andreas Fisch, Zaixing Li, Mika Lindvall, Heinz Ernst Moser, Michael Mutz, Folkert Reck, Bernd Ulrich Riebesehl, Marc Schoenhentz, Vijay Sethuraman, Robert Lowell Simmons
  • Publication number: 20180273522
    Abstract: The invention provides new solid forms, salts and polymorphs of 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid (referred to herein as Compound X), pharmaceutical compositions containing them, and processes for their manufacture and use in therapy.
    Type: Application
    Filed: September 20, 2016
    Publication date: September 27, 2018
    Inventors: Eric AUBIN, Anthony CASAREZ, Andreas FISCH, Zaixing LI, Mika LINDVALL, Heinz Ernst MOSER, Michael MUTZ, Folkert RECK, Bernd Ulrich RIEBESEHL, Marc SCHOENHENTZ, Vijay SETHURAMAN, Robert Lowell SIMMONS
  • Publication number: 20180118678
    Abstract: This invention relates to a hemifumarate salt of 1-(4- 1-[(E)-cyclohexyl-3-tritluoromethy 1-benzy loxyimino ]-ethy 1)-2-ethy1-benzy l)-azetidine-3-carboxy lie acid (Compound) to pharmaceutics compositions comprising this salt, to processes for forming this salt and to its use in medical treatment, addition, the present invention also relates to new polymorphic forms of the hemifumarate salt form of Compound I, as well as to pharmaceutical compositions comprising these polymorphic forms, to processes for obtaining them, and their use in medical treatment.
    Type: Application
    Filed: October 31, 2017
    Publication date: May 3, 2018
    Inventors: Lech CISZEWSKI, Marilyn DE LA CRUZ, Piotr H. KARPINSKI, Michael MUTZ, Christian RIEGERT, Caspar VOGEL, Ricardo SCHNEEBERGER
  • Publication number: 20150284364
    Abstract: The present invention relates to substituted indole derivatives, to processes for their production, to new stable forms, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: November 6, 2013
    Publication date: October 8, 2015
    Inventors: Nicole Bieri, Jörg Brozio, Wenjie Li, Michael Mutz, Rita Ramos, Lei Zhang
  • Publication number: 20150175536
    Abstract: This invention relates to a hemifumarate salt of 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2-ethyl-benzyl)-azetidine-3-carboxylic acid (Compound I), to pharmaceutical compositions comprising this salt, to processes for forming this salt and to its use in medical treatment. In addition, the present invention also relates to new polymorphic forms of the hemifumarate salt form of Compound I, as well as to pharmaceutical compositions comprising these polymorphic forms, to processes for obtaining them, and their use in medical treatment.
    Type: Application
    Filed: March 3, 2015
    Publication date: June 25, 2015
    Inventors: Lech CISZEWSKI, Marilyn DE LA CRUZ, Piotr H. KARPINSKI, Michael MUTZ, Christian RIEGERT, Caspar VOGEL, Ricardo SCHNEEBERGER
  • Patent number: 8946272
    Abstract: The invention relates to crystalline forms of 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid and to its amorphous form, to processes for the preparation thereof, to compositions containing the same and their uses for the manufacture of a medicament for the treatment of the human body.
    Type: Grant
    Filed: April 2, 2013
    Date of Patent: February 3, 2015
    Assignee: Novartis AG
    Inventor: Michael Mutz
  • Publication number: 20140323495
    Abstract: The invention relates to the stabilized amorphous form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)-pyrimidin-2-ylamino)-phenyl]-benzamide, pharmaceutical compositions such as capsules or tablets containing this form, the use of such form in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans, and the use of formulation principles stabilizing the amorphous form of Imatinib mesylate as an intermediate for the preparation of pharmaceutical compositions.
    Type: Application
    Filed: July 15, 2014
    Publication date: October 30, 2014
    Applicant: NOVARTIS AG
    Inventors: Elisabete Goncalves, Oskar Kalb, Michael Mutz, Wolfgang Wirth, Jay Parthiban Lakshman
  • Patent number: 8846706
    Abstract: Crystalline forms of imatinib mesylate (F, G, H, I and K) and their respective characterization are disclosed.
    Type: Grant
    Filed: July 15, 2011
    Date of Patent: September 30, 2014
    Assignee: Novartis AG
    Inventor: Michael Mutz
  • Publication number: 20140235722
    Abstract: The present invention relates to salts, polymorphs and hydrates of 2-Amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diol, and to the use thereof, in particular in the treatment or prevention of various autoimmune conditions.
    Type: Application
    Filed: February 13, 2014
    Publication date: August 21, 2014
    Applicant: NOVARTIS AG
    Inventors: Guido Jordine, Michael Mutz
  • Patent number: 8710216
    Abstract: The invention relates to a new crystalline form II of N-benzoyl-staurosporine; compositions containing the same; processes for the preparation thereof; and the use of crystalline form II of of N-benzoyl-staurosporine in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans. The invention relates to the amorphous forms of N-benzoyl-staurosporine; compositions containing the same; processes for the preparation thereof; and the use of amorphous N-benzoyl-staurosporine in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans.
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: April 29, 2014
    Assignee: Novartis AG
    Inventors: Pascale Hoehn, Bernd Koch, Michael Mutz
  • Patent number: 8680146
    Abstract: The present invention relates to salts, polymorphs and hydrates of 2-Amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diol, and to the use thereof, in particular in the treatment or prevention of various autoimmune conditions.
    Type: Grant
    Filed: November 10, 2009
    Date of Patent: March 25, 2014
    Assignee: Novartis AG
    Inventors: Guido Jordine, Michael Mutz
  • Publication number: 20140051766
    Abstract: The present invention relates to crystalline forms and hydrates of 2-Amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diol, and to the use thereof, in particular in the treatment or prevention of various autoimmune conditions.
    Type: Application
    Filed: August 12, 2013
    Publication date: February 20, 2014
    Applicant: Novartis AG
    Inventors: Guido Jordine, Michael Mutz
  • Publication number: 20140051853
    Abstract: The present invention relates to acid addition salts of 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, which are selected from the group consisting of a tartrate salt, such as a (D)(?) tartrate salt or a (L)(+) tartrate salt, a hydrochloride salt, a citrate salt, a malate salt, a fumarate salt, a succinate salt, a benzoate salt, a benzenesulfonate salt, a pamoate salt, a formate salt, a malonate salt, a 1,5-naphthalenedisulfonate salt, a salicylate salt, a cyclohexanesulfamate salt, a lactate salt, a mandelate salt, aq glutarate salt, an adipate salt, a squarate salt, a vanillate salt, an oxaloacetate salt, an ascorbate salt and a sulfate salt.
    Type: Application
    Filed: July 19, 2013
    Publication date: February 20, 2014
    Applicant: Novartis AG
    Inventors: Hans Michael Bürger, Paul William Manley, Michael Mutz
  • Patent number: 8633213
    Abstract: Crystalline forms of imatinib mesylate (F, G, H, I and K) and their respective characterization are disclosed.
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: January 21, 2014
    Assignee: Novartis AG
    Inventor: Michael Mutz
  • Publication number: 20140005162
    Abstract: This invention relates to a hemifumarate salt of 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2-ethyl-benzylyazetidine-3-carboxylic acid (Compound I), to pharmaceutical compositions comprising this salt, to processes for forming this salt and to its use in medical treatment. In addition, the present invention also relates to new polymorphic forms of the hemifumarate salt form of Compound I, as well as to pharmaceutical compositions comprising these polymorphic forms, to processes for obtaining them, and their use in medical treatment.
    Type: Application
    Filed: June 12, 2013
    Publication date: January 2, 2014
    Inventors: Lech CISZEWSKI, Marilyn DE LA CRUZ, Piotr H. KARPINSKI, Michael MUTZ, Christian RIEGERT, Caspar VOGEL, Ricardo SCHNEEBERGER
  • Patent number: 8592440
    Abstract: Crystalline forms of imatinib mesylate (F, G, H, I and K) and their respective characterizations are disclosed.
    Type: Grant
    Filed: July 15, 2011
    Date of Patent: November 26, 2013
    Assignee: Novartis AG
    Inventor: Michael Mutz
  • Publication number: 20130296556
    Abstract: The present invention relates to new salt forms of 5-(-2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide, in particular the mesylate, hydrochloride, lartrate, phosphate and hemi fumarate slat thereof; to crystalline forms of such salts; to polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-4-carboxylic acid ethylamide; to hydrates and polymorphs of the new salt forms mentioned above; to the use of the new salt forms mentioned above for the manufacture of a medicament for the treatment of a disorder mediated by Hsp90; to a method for treating a disorder mediated by Hsp90 using the new salt forms; to formulations comprising such salt forms, in particular aqueous solutions suitable for intravenous administration; and to amber glass containers being filled with such formulations.
    Type: Application
    Filed: July 10, 2013
    Publication date: November 7, 2013
    Applicant: Novartis AG
    Inventors: Martin James Drysdale, Brian William Dyrnock, Christoph Krell, Michael Mutz, Holger Petersen, Weijia Zheng
  • Publication number: 20130267572
    Abstract: The invention relates to crystalline forms of 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid and to its amorphous form, to processes for the preparation thereof, to compositions containing the same and their uses for the manufacture of a medicament for the treatment of the human body.
    Type: Application
    Filed: April 2, 2013
    Publication date: October 10, 2013
    Applicant: NOVARTIS AG
    Inventor: Michael Mutz
  • Patent number: 8530522
    Abstract: The present invention relates to crystalline forms and hydrates of 2-Amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diol, and to the use thereof, in particular in the treatment or prevention of various autoimmune conditions.
    Type: Grant
    Filed: November 10, 2009
    Date of Patent: September 10, 2013
    Assignee: Novartis AG
    Inventors: Guido Jordine, Michael Mutz
  • Publication number: 20130225598
    Abstract: The invention relates to the stabilized amorphous form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)-pyrimidin-2-ylamino)-pheny]-benzamide, pharmaceutical compositions such as capsules or tablets containing this form, the use of such form in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans, and the use of formulation principles stabilizing the amorphous form of Imatinib mesylate as an intermediate for the preparation of pharmaceutical compositions.
    Type: Application
    Filed: April 17, 2013
    Publication date: August 29, 2013
    Applicant: Novartis AG
    Inventors: Elisabete Goncalves, Oskar Kalb, Michael Mutz, Wolfgang Wirth, Jay Parthiban Lakshman